150 related articles for article (PubMed ID: 26050359)
21. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
[TBL] [Abstract][Full Text] [Related]
22. Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.
Preisler S; Rebolj M; Ejegod DM; Lynge E; Rygaard C; Bonde J
BMC Cancer; 2016 Jul; 16():510. PubMed ID: 27439470
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
Chung HS; Hahm C; Lee M
J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
[TBL] [Abstract][Full Text] [Related]
24. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
[TBL] [Abstract][Full Text] [Related]
25. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.
Schiffman M; Herrero R; Hildesheim A; Sherman ME; Bratti M; Wacholder S; Alfaro M; Hutchinson M; Morales J; Greenberg MD; Lorincz AT
JAMA; 2000 Jan; 283(1):87-93. PubMed ID: 10632285
[TBL] [Abstract][Full Text] [Related]
26. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
Ge Y; Christensen P; Luna E; Armylagos D; Schwartz MR; Mody DR
Cancer Cytopathol; 2017 Aug; 125(8):652-657. PubMed ID: 28574670
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
Li RZ; Shi JF; Zhou QZ; Wu RF; Li N; Wu LN; Zhou YQ; Wang Q; Liu ZH; Liu B; Qiao YL
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(5):307-11. PubMed ID: 16677522
[TBL] [Abstract][Full Text] [Related]
28. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
29. Clinical performance of the aptima HPV assay in 4196 women with positive high-risk HPV and ASC-US cytology: A large women hospital experience.
Wang T; Pradhan D; Zhang H; Matsko J; Zhao C
Diagn Cytopathol; 2021 Jan; 49(1):5-10. PubMed ID: 32857920
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study.
Thomsen LT; Dehlendorff C; Junge J; Waldstrøm M; Schledermann D; Frederiksen K; Kjaer SK
Int J Cancer; 2016 Oct; 139(8):1839-50. PubMed ID: 27004595
[TBL] [Abstract][Full Text] [Related]
31. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.
Cook DA; Smith LW; Law JH; Mei W; Gondara L; van Niekerk DJ; Ceballos KM; Jang D; Chernesky M; Franco EL; Ogilvie GS; Coldman AJ; Krajden M
J Clin Virol; 2018 Nov; 108():32-37. PubMed ID: 30223252
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
[TBL] [Abstract][Full Text] [Related]
34. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
35. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.
Halfon P; Trepo E; Antoniotti G; Bernot C; Cart-Lamy P; Khiri H; Thibaud D; Marron J; Martineau A; Pénaranda G; Benmoura D; Blanc B;
J Clin Microbiol; 2007 Feb; 45(2):313-6. PubMed ID: 17122007
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia.
Monsonego J; Pintos J; Semaille C; Beumont M; Dachez R; Zerat L; Bianchi A; Franco E
Int J Gynecol Cancer; 2006; 16(2):591-8. PubMed ID: 16681731
[TBL] [Abstract][Full Text] [Related]
38. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings.
Kuhn L; Denny L; Pollack A; Lorincz A; Richart RM; Wright TC
J Natl Cancer Inst; 2000 May; 92(10):818-25. PubMed ID: 10814677
[TBL] [Abstract][Full Text] [Related]
40. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation.
Weston G; Dombrowski C; Harvey MJ; Iftner T; Kyrgiou M; Founta C; Adams EJ
BMJ Open; 2020 Mar; 10(3):e031303. PubMed ID: 32152154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
